MX2010011006A - Nueva sal de un derivado de pirimidina. - Google Patents

Nueva sal de un derivado de pirimidina.

Info

Publication number
MX2010011006A
MX2010011006A MX2010011006A MX2010011006A MX2010011006A MX 2010011006 A MX2010011006 A MX 2010011006A MX 2010011006 A MX2010011006 A MX 2010011006A MX 2010011006 A MX2010011006 A MX 2010011006A MX 2010011006 A MX2010011006 A MX 2010011006A
Authority
MX
Mexico
Prior art keywords
pyrimidin
new salt
derivative
pyrimidin derivative
salt
Prior art date
Application number
MX2010011006A
Other languages
English (en)
Inventor
Juan Pablo Senosiain Pelaez
Hector Senosiain Arroyo
Manuel Francisco Lara Ochoa
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Priority to MX2010011006A priority Critical patent/MX2010011006A/es
Priority to ES201390034A priority patent/ES2409805B1/es
Priority to US13/877,887 priority patent/US8846708B2/en
Priority to CA2813388A priority patent/CA2813388A1/en
Priority to BR112013008330A priority patent/BR112013008330A2/pt
Priority to PCT/IB2011/054369 priority patent/WO2012046193A1/es
Publication of MX2010011006A publication Critical patent/MX2010011006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende una sal de un derivado pirimídico de ácido (3R,5S,6E)-7-[4-(4-fluorofenil)-2-(N-metilmetanesulfonami do)-6-(propan-2-il)pirimidin-5-il]-3,5-dihidroxihepta-6-enóico, un procedimiento para su preparación y el uso para la elaboración de formulaciones farmacéuticas.
MX2010011006A 2010-10-06 2010-10-06 Nueva sal de un derivado de pirimidina. MX2010011006A (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2010011006A MX2010011006A (es) 2010-10-06 2010-10-06 Nueva sal de un derivado de pirimidina.
ES201390034A ES2409805B1 (es) 2010-10-06 2011-10-04 Nueva sal de un derivado de pirimidina
US13/877,887 US8846708B2 (en) 2010-10-06 2011-10-04 Salt of a pyrimidin derivative
CA2813388A CA2813388A1 (en) 2010-10-06 2011-10-04 New salt of a pyrimidin derivative
BR112013008330A BR112013008330A2 (pt) 2010-10-06 2011-10-04 novo sal de um derivado de piridina
PCT/IB2011/054369 WO2012046193A1 (es) 2010-10-06 2011-10-04 Nueva sal de un derivado de pirimidina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010011006A MX2010011006A (es) 2010-10-06 2010-10-06 Nueva sal de un derivado de pirimidina.

Publications (1)

Publication Number Publication Date
MX2010011006A true MX2010011006A (es) 2012-04-18

Family

ID=45927285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011006A MX2010011006A (es) 2010-10-06 2010-10-06 Nueva sal de un derivado de pirimidina.

Country Status (6)

Country Link
US (1) US8846708B2 (es)
BR (1) BR112013008330A2 (es)
CA (1) CA2813388A1 (es)
ES (1) ES2409805B1 (es)
MX (1) MX2010011006A (es)
WO (1) WO2012046193A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103232398B (zh) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 一种瑞舒伐他汀氨基酸盐及其制备方法和应用
WO2014154856A1 (en) * 2013-03-29 2014-10-02 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pravastatin and rosuvastatin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HUP0201083A2 (hu) * 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
SG178721A1 (en) 2003-07-29 2012-03-29 Signature R & D Holdings Llc Amino acid prodrugs
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül

Also Published As

Publication number Publication date
ES2409805R1 (es) 2013-07-15
ES2409805A2 (es) 2013-06-27
ES2409805B1 (es) 2014-03-19
BR112013008330A2 (pt) 2016-06-14
WO2012046193A1 (es) 2012-04-12
CA2813388A1 (en) 2012-04-12
US20130210848A1 (en) 2013-08-15
US8846708B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
MY178634A (en) Topical formulation for a jak inhibitor
MY158193A (en) Morpholino pyrimidines and their use in therapy
PH12015500780A1 (en) Rsv antiviral compounds
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
MY180039A (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
MX2014004603A (es) Formas de dosificacion solidas de 2-amino-3-(4-(2-amino-6-((r)-1-( 4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pi rimidin-4-il)fenil) propanoato de (s)-etilo.
UA112423C2 (uk) Спосіб одержання (варіанти) кристалічних форм розувастатину тба
MX2013005960A (es) Metodo para preparar sales de rosuvastatina.
MX2010011006A (es) Nueva sal de un derivado de pirimidina.
EA032913B1 (ru) Препараты производных пиримидиндиона
NZ630251A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
NZ705994A (en) Process for preparing pemetrexed di potassium and its hydrates
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
UA103544C2 (uk) Кристалічна форма і цинкової солі розувастатину
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
WO2009095712A3 (en) 4-(3-amin0pyraz0le) pyrimidine derivatives for use as jak kinase inhibitors in the treatment of cancer
IN2013CH05870A (es)
HU1000616D0 (en) Crystalline pharmaceutically active ingredient
MY190433A (en) Heterocyclic compounds and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration